<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Bariatric surgery consistently induces remission of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We tested whether there are <z:mp ids='MP_0002055'>diabetes</z:mp>-specific mechanisms in addition to <z:hpo ids='HP_0001824'>weight loss</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We studied 25 morbidly <z:mp ids='MP_0001261'>obese</z:mp> patients (BMI 51.7 ± 1.5 kg/m(2) [mean ± <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>]), 13 with non-insulin-treated type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (HbA(1c) 7.1 ± 0.5% [54 ± 5 mmol/mol]), before and at 2 weeks and 1 year after Roux-en-Y gastric bypass (RYGB) </plain></SENT>
<SENT sid="3" pm="."><plain>Lean (n = 8, BMI 23.0 ± 0.5 kg/m(2)) and <z:mp ids='MP_0001261'>obese</z:mp> (n = 14) volunteers who were BMI-matched (36.0 ± 1.2) to RYGB patients at 1 year after surgery served as controls </plain></SENT>
<SENT sid="4" pm="."><plain>We measured insulin-stimulated <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal (M) and substrate utilisation (euglycaemic clamp/indirect calorimetry), endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> production (EGP) by 6,6-[(2)H(2)]<z:chebi fb="105" ids="17234">glucose</z:chebi>, lipolysis (rate of appearance of [(2)H(5)]<z:chebi fb="3" ids="17754">glycerol</z:chebi>) and beta cell function (<z:hpo ids='HP_0011009'>acute</z:hpo> insulin response to i.v. <z:chebi fb="105" ids="17234">glucose</z:chebi> [AIR] as determined by C-<z:chebi fb="7" ids="16670">peptide</z:chebi> deconvolution) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: At baseline, <z:hpo ids='HP_0000001'>all</z:hpo> <z:mp ids='MP_0001261'>obese</z:mp> groups showed typical <z:mp ids='MP_0005266'>metabolic abnormalities</z:mp>, with M, <z:chebi fb="105" ids="17234">glucose</z:chebi> oxidation and non-oxidative disposal impaired, and EGP, lipolysis, <z:chebi fb="23" ids="18059">lipid</z:chebi> oxidation and energy expenditure increased </plain></SENT>
<SENT sid="6" pm="."><plain>Early after RYGB plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> and insulin levels, and energy expenditure had decreased, while <z:chebi fb="23" ids="18059">lipid</z:chebi> oxidation increased, with M, EGP and AIR unchanged </plain></SENT>
<SENT sid="7" pm="."><plain>At 1 year post-RYGB (BMI 34.4 ± 1.1 kg/m(2)), <z:hpo ids='HP_0000001'>all</z:hpo> diabetic patients were off <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering treatment and mean HbA(1c) was 5.4 ± 0.14% (36 ± 2 mmol/mol) (p = 0.03 vs baseline); AIR also improved significantly </plain></SENT>
<SENT sid="8" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> RYGB patients, M, substrate oxidation, EGP, energy expenditure and lipolysis improved in proportion to <z:hpo ids='HP_0001824'>weight loss</z:hpo>, and were therefore similar to values in <z:mp ids='MP_0001261'>obese</z:mp> controls, but still different from those in lean controls </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATION: In morbidly <z:mp ids='MP_0001261'>obese</z:mp> patients, RYGB has metabolic effects on liver, adipose tissue, muscle insulin sensitivity and pattern of substrate utilisation; these effects can be explained by energy intake restriction and <z:hpo ids='HP_0001824'>weight loss</z:hpo>, the former prevailing early after surgery, the latter being dominant in the longer term </plain></SENT>
</text></document>